Screening of growth impairment in juvenile rheumatoid arthritis systemic lupus erythematoosus and autoimmune chronic liver disorders

الملخص EN

Introduction: Autoimmune diseases are frequently associated with growth impairment.

This may be a consequence of the inflammatory process associated with disease activity and is also caused by the high- dose corticosteroids that are often used for treatment.

Aim: Screening of growth impairment in juvenile rheumatoid arthritis, systemic lupus erythematosus and autoimmune chronic liver disorders.

Subjects and methods: One thousand cases of school age children of both sexes of juvenile rheumatoid arthritis, systemic lupus erythematosus and autoimmune chronic liver disorders, the study will be conducted in the 4 main pediatric hospitals in Alexandria, to detect growth impairment in those children as indicated by auxological parameters from June 2010 to August 2015.

Results: In the studied juvenile rheumatoid arthritis (No.

593) group of school male (No.

118) and female (No.

475) children <3rd- < 10th height for age percentile category (short stature) the percentage in males and females were 51.7 and 46,5 respectively, which were the highest percentages are statistically significant and in the studied autoimmune chronic liver disorders (ACLD) group of school age female (No.

69) children and adolescents in the short stature category (<3rd- <10th height for age percentile) a high percentage was observed which was 45.5 that is statistically significant.

Pubertal assessment (Tanner staging) of the studied systemic lupus erythematosus (SLE) group of school age male children and adolescents (No.

69) shows that 48% of cases were in the Tanner stage 1 category is statistically significant which means delayed puberty was in a large number of this cases.

Conclusion: Juvenile rheumatoid arthritis, systemic lupus eryth-ematosus and autoimmune chronic liver disorders are frequently associated with growth impairment and delayed puberty.

It is important to regularly monitor physical development and control inflammation associated with disease activity.